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Introduction: Most pregnant smokers report abruptly reducing their cigarettes per day 
(CPD) by ~50% shortly after learning of pregnancy and of making further smaller 
reductions over the remainder of their pregnancy. Laboratory and naturalistic studies with 
non-pregnant smokers have found that these types of reductions often lead to changes in 
smoking topography (i.e., changes in smoking intensity to maintain a desired blood-
nicotine level). 19, 20 If pregnant women engage in compensatory smoking, they may 
expose themselves and their offspring to the same level of toxicants despite reporting 
reductions in CPD.  
Methods: Pregnant and non-pregnant female smokers (n = 17 and 91, respectively) 
participated.  At the experimental session, after biochemical confirmation of acute 
abstinence, all participants smoked one of their usual brand cigarettes ad lib through a 
Borgwaldt CReSS Desktop Smoking Topography device. Carbon monoxide (CO) and 
measures of nicotine withdrawal, craving, and reinforcement derived from smoking were 
also collected.   
Results: The two groups did not differ on any demographic or smoking characteristics at 
screening, except nicotine metabolism rate, which as expected, was faster in pregnant 
smokers. Analyses suggest that none of the smoking topography parameters differed 
between pregnant and non-pregnant smokers, although pregnant smokers had a 
significantly smaller CO boost.  Both groups reported similar levels of relief of 
withdrawal and craving after smoking, but other self-report data suggest that pregnant 
smoker find smoking less reinforcing than non-pregnant smokers. 
Conclusions: Pregnant smokers do not smoke cigarettes differently as compared to non-
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Comprehensive Literature Review 
 Smoking during pregnancy is the leading preventable cause of poor pregnancy 
outcomes in the U.S. (U.S. Department of Health and Human Services [USDHHS], 
2014).  Women who smoke during pregnancy put themselves and their children at 
increased risk for a wide range of poor outcomes (Dietz et al., 2010; Hackshaw, Rodeck, 
& Boniface, 2011). Smoking while pregnant increases the risk of placental abruption, 
placenta previa, and miscarriage (Aliyu et al., 2011; Pineles, Park & Samet, 
2014).  Adverse fetal and neonatal effects include intrauterine growth restriction, low 
birth weight, preterm birth and birth defects (Cohen, Jeffery, Lagercrantz, & Katz-
Salamon, 2010; Dietz et al., 2010; Hackshaw et al., 2011) which contribute to longer, and 
therefore more costly, postnatal hospital stays (Adams, Melvin, Raskind-Hood, Joski, & 
Galactionova, 2011).  The adverse consequences continue into childhood and beyond in 
the form of increased risk for sudden infant death syndrome (SIDS), cognitive 
impairments, obesity, metabolic syndrome, Type 2 diabetes, and cardiovascular disease 
(Cohen et al., 2010; Bruin, Gerstein, & Holloway, 2010; Heinonen, et al., 2011; Moylan 
et al., 2015).   
Changes in Smoking during Pregnancy 
Most pregnant women know that smoking during pregnancy increases adverse 
outcomes for both the fetus/neonate and the mother (Arnold et al., 2001) and also report 
being the target of strong social stigma (Abrahamsson, Springett, Karlsson, & Ottosson, 
2005; Wigginton & Lee, 2013).  Nonetheless, most women cannot quit smoking on their 
own after learning of pregnancy (Heil et al., 2014; Solomon & Quinn, 2004). Instead, 
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most report spontaneously reducing their cigarette use in an effort to reduce fetal toxicant 
exposure (Graham, Flemming, Fox, Heirs, & Sowden, 2014).  Across a wide variety of 
studies, the majority of pregnant smokers reliably report decreasing their cigarettes per 
day (CPD) by approximately 50% between learning of pregnancy and entering prenatal 
care (Coleman et al., 2012; Dornelas et al., 2006; Heil et al., 2008; Higgins et al., 2004; 
Higgins et al., 2014; Pollak et al., 2007; Rigotti et al., 2006; Ussher et al., 2015) and 
recent work by our group examined the time course of this change for the first time (Heil 
et al., 2014). In our research clinic, women enrolling in clinical trials testing whether 
financial incentives increase abstinence in pregnant smokers complete a timeline follow-
back interview where they retrospectively self-reported their CPD each day between 
when they learned they were pregnant and when they entered prenatal care an average of 
five weeks later.  This analysis specifically characterized the timing of CPD reductions in 
the days after learning 
of pregnancy in 107 of 
these women. Results 
indicated that 22% 
reported quitting 
smoking between 
learning of pregnancy 
and entering prenatal 
care, 62% significantly 
reduced the number of 
Figure 1. Mean ± standard error of the mean for cigarettes/day before and after learning 
of pregnancy among women who self-report reducing cigarettes/day upon learning of 
pregnancy.  Adapted from “Examining the timing of changes in cigarette smoking upon 
learning of pregnancy,” by S. H> Heil, E.S. Herrmann, G. J. Badger, L. J. Solomon, I. 
M. Bernstein, S. T. Higgins, Preventive Medicine, 68, 58-61. 
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cigarettes they smoked each day, and 16% reported making no changes in their smoking 
at all during this time period.  Focusing on those who reduced, as expected, most reported 
a characteristic 50% reduction in CPD.  Interestingly, most of this reduction occurred in 
the first two days after learning of pregnancy (Figure 1), a remarkable reduction over a 
short period given the persistent and tenacious nature of cigarette smoking.  A potential 
limitation of these data is our use of self-reported CPD.  As noted previously, stigma 
could be expected to contribute to some extent of under-reporting of smoking rates, 
although this clearly did not prevent the majority of participants from reporting continued 
smoking and a sizeable percentage from reporting that they had not changed their 
smoking at all since learning of pregnancy.  Nevertheless, without biochemical data, it is 
difficult to know whether self-reported reductions in CPD truly decrease toxicant 
exposure. 
Correspondence between Self-Report and Biochemical Measures of Cigarette Use.  
To examine this further, we conducted another analysis where the correspondence 
between self-report and biochemical measures of smoking could be assessed (Heil, 
Solomon, Skelly, Bernstein, & Higgins, 2015). Data were collected from a different set of 
pregnant women participating in the same series of randomized clinical trials testing 
financial incentives for smoking cessation described above.  CPD and biochemical 
measures of smoking were examined among a subset of 156 women who reported 
smoking and had complete data at each of three research assessments completed during 
the pregnancy, the first at Intake at ~10 weeks gestation, the second four weeks later 
(Early Pregnancy), and the third at approximately ~28 weeks gestation (Late Pregnancy). 
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The biochemical measures of 
smoking were breath carbon 
monoxide (CO) and urine 
cotinine.  CO is one of the 
primary toxic components of 
cigarette smoke.  The elimination 
half-life of CO is only a few 
hours (Jarvis, Tunstall-Pedoe, 
Feyerabend, Vesey, & Saloojee, 
1987), thus levels are indicative 
of very recent smoking. 
Cotinine is the primary 
metabolite of nicotine.  The elimination half-life is approximately five times longer than 
that of CO (Dempsey, Jacob & Benowitz, 2002), making it a better measure of smoking 
over the last few days.  On average, women in this analysis reported further significant 
reductions in CPD, from 11 CPD at Intake to 7-8 CPD at the Early and Late Pregnancy 
assessments (Figure 2). Despite this significant 31% decrease in CPD between the Intake 
and Early Pregnancy assessments, however, urine cotinine only decreased by 10% and 
breath CO did not change appreciably.  At the Late Pregnancy assessment, urine cotinine 
was not statistically different from Early Pregnancy assessment.  
Prior studies of the correspondence between self-report and biochemical measures 
of smoking in pregnant women have often reported similar discrepancies and have 
Figure 2. Mean ± SEM urine cotinine in nanograms per milliliter, breath CO in parts 
per million and cigarettes per day at ~ 10 weeks estimated gestational age (Intake), ~ 
14 weeks estimated gestational age (Early Pregnancy) and ~26 weeks estimated 
gestational age (Late Pregnancy).  Data points with letters in common are not 
statistically different from one another.  Repeated measures ANOVAs indicated a 
significant effect of time on urine cotinine and CPD but not CO.  Data points with 
letters in common were not statistically different from one another in post hoc 
analyses. Adapted from “Correspondence between Self-Report and Biochemical 
Measures of Cigarette Use in Pregnant Women” by S. H. Heil, L. J. Solomon, J. M. 
Skelly, I. M. Bernstein, & S. T. Higgins, presented at the College on Problems of 
Drug Dependence Annual meeting, June 2015. 
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frequently hypothesized that (1) inaccurate self-report, (2) changes in metabolism, and/or 
(3) changes in smoking topography account for these inconsistencies (Boyd, Windsor, 
Perkins & Lowe, 1998; Dukic, Niessner, Benowitz, Hans, & Wakschlag, 2007; Ellard, 
Johnstone, Prescott, Ji-Xian, & Jian-Hua, 1996; Klebanoff, Levine, Clemens, 
DerSimonian, & Wilkins, 1998; Lindqvist, Lendahls, Tollbom, Aberg, & Hakansson, 
2002; Pickett, Rathouz, Kasza, Wakschlag, & Wright, 2005).  In the sections that follow, 
current knowledge about each of these potential explanations is briefly reviewed.   
Inaccurate Self-Report among Pregnant Smokers.  As with the use of any 
drug, it is not recommended to rely on self-report of smoking as participants may be 
unable or unwilling to accurately report use (Connor Gorber, Schofield-Hurwitz, Hardt, 
Levasseur, & Tremblay, 2009; Magura & Kang, 1996; National Institute of Drug Abuse, 
2012).  As a result, self-report is often verified by biochemical markers of smoking like 
breath CO and urine cotinine.  Many studies have examined the relationship between 
self-report and biochemical markers of smoking among pregnant women and used these 
data to estimate the rate of inaccurate reporting in terms of smoking status (i.e., 
differentiating smokers from nonsmokers) as well as smoking rate (e.g., differentiating 
lighter, moderate, and heavier smokers from each other).  One review of 15 studies found 
that the rate of inaccurate self-report of smoking status ranged between 0-35%, with a 
median of 21% (Russell, Crawford, & Woodby, 2004).  There are fewer studies 
examining smoking rate, but similar to smoking status, correlations between CPD and 
biochemical markers tend to vary widely, with a range of .32 - .74 and a median of .44 
(Boyd et al., 1998; Ellard et al., 1996; Klebanoff et al. 1998; Pickett et al., 2005).  Given 
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strong social stigma against smoking during pregnancy, it is not surprising that pregnant 
women might underreport smoking status and rate.  But because estimations of 
underreporting are based on studies of the relationship between self-report and levels of 
biochemical markers, and levels of biochemical markers could be altered by metabolism 
and topography differences during pregnancy, it has remained unclear how much of the 
discrepancy between self-report and biochemical markers is due to true inaccurate self-
report and how much could be due to confounding changes in metabolism and/or 
smoking topography. In fact, most of the studies in this literature have used biochemical 
cut points that were based on cut points established for non-pregnant smokers as there 
were few data on metabolism and topography during pregnancy to guide adjustments.  In 
the next two sections, the extant data on metabolism and topography during pregnancy 
are reviewed.   
Changes in Metabolism among Pregnant Smokers. Dempsey and colleagues 
conducted the seminal study of nicotine and cotinine metabolism during the perinatal 
period.  In this within-subject study, pregnant women were admitted inpatient and infused 
with labeled nicotine and cotinine to determine the pharmacokinetics of each drug.  The 
procedure was then repeated during the postpartum period.  Given the common report of 
substantial smoking reductions among pregnant women, the authors hypothesized that 
nicotine and cotinine metabolism would be slower during pregnancy. Surprisingly, the 
data indicated higher rates of metabolism during pregnancy as compared to postpartum 
(Dempsey et al., 2002).  For example, nicotine clearance was 60% faster during 
pregnancy vs. postpartum.  While this study documented this change for the first time, 
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the design of the study left the timing of the change unclear.   
A recent longitudinal cohort study by Bowker and colleagues (2015) begins to 
help clarify the timing (Bowker, Lewis, Coleman & Cooper, 2015). Rather than infusing 
nicotine and directly measuring subsequent metabolism, these investigators used a 
simple, but validated, method to estimate nicotine metabolism in biological matrices 
known as the nicotine metabolite ratio (NMR; Dempsey et al., 2004; Levi, Dempsey, 
Benowitz, & Sheiner, 2007).  NMR is calculated by dividing the level of trans-3’-
hydroxycotinine, the primary metabolite of cotinine, by the level of cotinine.  In the 
Bowker et al. (2015) study, pregnant women (N=101) were asked to provide saliva 
samples at three time points throughout their pregnancy and twice postpartum.  Each 
sample was assayed for trans-3’-hydroxycotinine and cotinine and an NMR was 
calculated.  Compared to their NMR at 12 weeks postpartum, NMR approached statistical 
significance at 8-14 weeks and was significantly higher at 18-22 and 32-36 weeks 
estimated gestational age, but was lower and not significantly different at 4 weeks 
postpartum.  These results confirm Dempsey et al.’s findings of higher rates of 
metabolism during pregnancy and further suggest that nicotine metabolism accelerates 
very early in the pregnancy, remains elevated throughout the pregnancy, and returns to 
lower levels early in the postpartum period.   
More recently, our group examined the time course of NMR changes during 
pregnancy and postpartum. Forty-six women enrolled in a trial to test the effectiveness of 
financial incentives to increase abstinence among pregnant smokers and who continued 
to smoke during pregnancy and into postpartum provided urine samples at two 
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assessments during pregnancy at ~10 weeks and ~28 weeks estimated gestational age and 
one assessment at 6 months postpartum. Consistent with the two earlier reports, NMR 
was significantly higher at both pregnancy assessments compared to the postpartum 
assessment.  Additionally, NMR was significantly higher at the later pregnancy 
assessment compared to the earlier pregnancy assessment, adding credence to the 
borderline trend observed by Bowker and colleagues. Since metabolism appears to 
increase throughout the antepartum period, it is unlikely that metabolism differences 
explain the discrepancies between self-report and biochemical measures of smoking 
described above.   
Changes in Smoking Topography among Pregnant Smokers.  To our 
knowledge, there are no data examining smoking topography in pregnant smokers.  
However, data from non-pregnant smokers suggests that reductions in CPD like those 
reported by pregnant smokers might lead to changes in smoking topography.  In a 
rigorous laboratory study on this topic, participants who normally smoked 37 CPD during 
unrestricted use were given only 15, 10 and 5 cigarettes a day while residing on an 
inpatient clinical research ward (Benowitz, Jacob, Kozlowski & Yu, 1986). Researchers 
collected urine and blood samples at regular intervals to measure changes in the levels of 
tar (a toxic byproduct of combusted tobacco), nicotine, and carboxyhemoglobin 
(indicative of decreased oxygen delivery throughout the body). Of particular interest here 
are the changes in these measures of cigarette exposure when participants went from 
smoking 37 CPD to 15 CPD, a 60% reduction, as this reduction most closely 
approximates the 50% reduction typically reported by pregnant smokers upon learning of 
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pregnancy (Heil et al., 
2014 and Figure 1 in 
this document). When 
participants in the 
Benowitz et al. study 
decreased their CPD 
by 60%, tar, nicotine, 
and 
carboxyhemoglobin 
levels only decreased 
by 15%, 32%, and 
26%, respectively (Figure 3).   While statistically significant, these decreases were not 
proportional to the reduction in CPD.  It was also notable that none of the participants 
reported any difficulty smoking just 15 CPD, with some participants quoted as saying it 
was “no hardship” and that it was “very easy”.  Similar, but more extreme results were 
observed when smokers were limited to 10 and 5 CPD (73% and 86% reductions, 
respectively).  The authors concluded that participants changed their smoking topography 
when the number of CPD was limited, likely by puffing on each cigarette more 
frequently and/or more intensely, to maintain their desired nicotine blood levels.    
A similar conclusion was reached in a more naturalistic longitudinal analysis of 
cross-sectional data collected in the National Health and Nutrition Examination Survey.  
The authors compared daily CPD and levels of serum cotinine in nationally 
Figure 3. Percent change in cigarettes, tar, nicotine and carboxyhemoglobin 
per 24 hours during unrestricted and restricted cigarette use.  Significant 
differences are indicated by an asterisk.  Adapted from “Influence of smoking 
fewer cigarettes on exposure to tar, nicotine and carbon monoxide.” By N. L. 
Benowitz, P. Jacob, L. T. Kozlowski, & L. Yu, 1986, The New England 
Journal of Medicine, 315, 1310-1316. 
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representative samples of cigarettes smokers assessed between 1988-1994 to those 
assessed between 1999-2012 (Jarvis, Giovino, O’Connor, Kozlowski & Bernert, 2014).  
The results indicated that mean CPD decreased significantly over time from 17.3 to 13.9 
CPD, a 20% reduction, very similar to the changes reported by pregnant smokers in early 
pregnancy (Heil et al., 2015 and Figure 2 in this document).  However, serum cotinine 
levels were not significantly different, decreasing from 223.7 to just 219.2 ng/ml, a 2% 
reduction. The authors conclude that these results are suggestive of increased inhalation 
to offset reduced cigarette consumption.  Together, the results of these two studies 
suggest that smokers maintain nicotine exposure after reducing their CPD by engaging in 
compensatory smoking, which in turn continues to expose them to similar levels of 
toxicants.   
Current Study 
 Whether changes in smoking topography help account for the apparent 
discrepancies between self-reported CPD and biochemical markers of smoking among 
pregnant smokers has not been examined to date to our knowledge.  If it is determined 
that pregnant women do smoke cigarettes more intensely than non-pregnant women, 
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Introduction: Most pregnant smokers report abruptly reducing their cigarettes per day 
(CPD) by ~50% shortly after learning of pregnancy and of making further smaller 
reductions over the remainder of their pregnancy. Laboratory and naturalistic studies with 
non-pregnant smokers have found that these types of reductions often lead to changes in 
smoking topography (i.e., changes in smoking intensity to maintain a desired blood-
nicotine level). 19, 20 If pregnant women engage in compensatory smoking, they may 
expose themselves and their offspring to the same level of toxicants despite reporting 
reductions in CPD.  
Methods: Pregnant and non-pregnant female smokers (n = 17 and 91, respectively) 
participated.  At the experimental session, after biochemical confirmation of acute 
abstinence, all participants smoked one of their usual brand cigarettes ad lib through a 
Borgwaldt CReSS Desktop Smoking Topography device. Carbon monoxide (CO) and 
measures of nicotine withdrawal, craving, and reinforcement derived from smoking were 
also collected.   
Results: The two groups did not differ on any demographic or smoking characteristics at 
screening, except nicotine metabolism rate, which as expected, was faster in pregnant 
smokers. Analyses suggest that none of the smoking topography parameters differed 
between pregnant and non-pregnant smokers, although pregnant smokers had a 
significantly smaller CO boost.  Both groups reported similar levels of relief of 
withdrawal and craving after smoking, but other self-report data suggest that pregnant 
smoker find smoking less reinforcing than non-pregnant smokers.  
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Conclusions: Pregnant smokers do not smoke cigarettes differently as compared to non-




















Maternal cigarette smoking is the leading preventable cause of poor pregnancy 
outcomes.1 Despite this, approximately 15% of pregnant women are regular cigarette 
smokers. Fifty percent reductions in cigarettes per day (CPD) in early pregnancy have 
been reliably reported across many studies.2-6 In one study by our group, pregnant women 
self-reported that the bulk of this change in smoking behavior takes place within the first 
few days after learning of their pregnancy.7   Surprisingly, this reduction in CPD occurs 
despite an increase in the metabolism of nicotine during pregnancy;8, 9 in non-pregnant 
populations, higher rates of nicotine metabolism are associated with smoking more 
CPD.10  
While pregnant smokers report making reductions in CPD to reduce harm to their 
offspring,11 previous research indicates that self-reported reductions do not necessarily 
correspond with toxicant reduction.  Data from our research group indicate that self-
reported reductions in CPD among pregnant smokers enrolled in a clinical trial to 
increase abstinence with financial incentives are not always paralleled by the same level 
of reduction in biochemical markers of smoking.12 Specifically, despite having reported a 
one third reduction in CPD between 10 weeks and 14 weeks gestation, urine cotinine 
levels among those pregnant smokers reduced by only 10% and carbon monoxide (CO) 
levels remained unchanged. Research by others tells a similar story: correlations between 
CPD and biochemical markers tend to vary widely among pregnant smokers, with a range 
across reports of .32 - .74 and a median of .44.13-16 
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One commonly cited potential explanation for variations in the relationship 
between nicotine exposure and CPD is that pregnant smokers change their smoking 
topography (e.g., increase the number of puffs per cigarette, the duration of each puff, the 
volume of each puff, etc.) in an effort to maintain the same blood nicotine level despite 
smoking fewer CPD (i.e., compensatory smoking).13-18 To our knowledge, no studies 
have examined smoking topography among pregnant smokers, but evidence from 
laboratory studies and naturalistic studies with non-pregnant smokers report similar 
discrepancies between the level of reduction in CPD and the level of reductions in 
smoking biomarkers that have been attributed to changes in smoking topography.19, 20 If 
pregnant women engage in compensatory smoking, they may expose themselves and 
their offspring to the same level of toxicants despite reporting reductions in CPD. The 
present study compared the smoking topography of usual brand cigarettes in non-
pregnant women of low socioeconomic status (SES) to pregnant smokers who have 
reported reductions in their CPD since learning of their pregnancy.   
METHOD 
Participants and Inclusion/Exclusion Criteria 
Pregnant and non-pregnant smokers were recruited via ads on Facebook, 
Craigslist, and in local newspapers; flyers on community bulletin boards; and from a 
local OB/GYN clinic.  All potential participants completed a brief phone screen and those 
who appeared eligible were invited to attend an in-person screening session to determine 
final eligibility.  After providing informed consent, participants submitted breath samples 
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(Micro+ Smokerlyzer; coVita/Bedfont, Haddonfield, NJ) and urine samples (NicAlert 
cotinine test strip; Nymox, Hasbrouck Heights, NJ) to verify smoking status.  Urine was 
also tested to determine pregnancy status and to quantify cotinine levels via enzyme 
immunoassay (MGC240; Microgenics, Fremont, CA).  Additionally, participants 
provided saliva samples which were analyzed for cotinine and trans-3’-hydroxycotinine 
(3-HC), the major metabolite of cotinine. 3-HC was divided by cotinine to calculate a 
nicotine metabolite ratio (NMR), which is strongly correlated with nicotine clearance.21   
Next, potential participants completed demographic (e.g., age, race/ethnicity, 
education, marital status, etc.) and medical history questionnaires developed in our 
laboratory, and then filled out a series of standardized questionnaires about their tobacco 
use, including the Fagerstrӧm Test for Nicotine Dependence 22-24 (see Appendix A).  
Eligible non-pregnant participants had to self-report smoking at least 5 CPD for 
the past year and have an intake breath CO sample > 8 ppm.  There was no minimum 
CPD or breath CO level for the pregnant participants.  Rather, smoking status was 
confirmed among pregnant participants with a urine cotinine value > 100 ng/ml (> 2 on 
NicAlert strip).  Low SES was also an inclusion criterion because socioeconomically 
disadvantaged women are at increased risk for (1) smoking, (2) nicotine dependence, (3) 
smoking more CPD, (4) smoking higher nicotine yield cigarettes and (5) continuing to 
smoke after becoming pregnant. 25, 26 Education level served as a proxy for SES and all 
participants had to have less than an Associate’s degree.  Individuals were excluded if 
they reported exclusively rolling their own cigarettes, if they reported using other tobacco 
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or nicotine products more than 9 days in the last 30 days, if they reported intentions to 
quit in the next 7 days if pregnant and 30 days if non-pregnant, or if they reported any 
smoking cessation product use in the last 30 days.  All participants were without current 
serious mental disorder.  Participants also could not show evidence of recent illicit drug 
use, but opioid-dependent women who were stable in opioid agonist maintenance 
treatment were eligible. “Stable” was defined as having (1) >70% of urine drug screens in 
the past month negative for all drugs of abuse and (2) been on the same methadone or 
buprenorphine dose for the past 7 days if pregnant and 30 days if not pregnant.  Pregnant 
women experience an acceleration in the metabolism of opioid agonist medication during 
pregnancy, so dose increases to prevent opioid withdrawal are not uncommon.27, 28. 
Stability in treatment was confirmed with treatment providers.  All potential participants 
were compensated $50 for completing the screening session.  
Procedures 
If deemed eligible, participants were invited back for an experimental session.  
Participants were instructed to abstain prior to the session and had to meet at least a 50% 
reduction in their screening breath CO level in order to begin the experimental session; 
this criterion is widely used as a marker of acute abstinence in smoking research.29, 30 
After abstinence was confirmed, all participants took two puffs from their usual brand 
cigarette to equate time since last cigarette.  Thirty minutes after taking two puffs, 
participants smoked one usual brand cigarette through a CReSS Desktop smoking 
topography device (Borgwaldt, Richmond, VA) with no instruction (i.e., ad libitum 
 18   
 
 
puffing) (see Appendix B). The device measured and recorded a number of smoking 
topography parameters, namely: (1) number of puffs per cigarette, (2) puff duration, (3) 
inter-puff interval, (4) puff volume and (5) maximum puff velocity (see Appendix C).  
The CReSS smoking topography device has been shown to have good reliability and 
validity.31, 32 This part of the session took place in a room with a ventilation system 
specifically designed to allow for cigarette smoking indoors.     
Immediately after smoking the cigarette, participants completed the modified 
Cigarette Evaluation Questionnaire (mCEQ).  The mCEQ consists of 12 items which 
query how smoking the cigarette made the participant feel (e.g., “Did the cigarette taste 
good?”, “Did the cigarette help you concentrate?”) (see Appendix D). 33 Designated items 
are averaged to generate five subscale scores, namely (1) Satisfaction, (2) Psychological 
Reward, (3) Aversion, (4) Enjoyment of Respiratory Tract Sensations and (5) Craving 
Reduction.  The measure has demonstrated good reliability and validity. 34    
CO was collected in 15-minute increments in the hour that followed smoking to 
assess CO boost, another measure of smoke exposure and intensity of smoking.35, 36 To 
measure CO boost, pre-cigarette CO was subtracted from each CO value measured after 
smoking the cigarette.  Withdrawal and craving were also measured in 15-minute 
increments using the Minnesota Nicotine Withdrawal Scale (MNWS) and Questionnaire 
of Smoking Urges-Brief Scale (QSU).  The MNWS measured eight nicotine withdrawal 
symptoms (e.g., craving, irritability, anxiety) (see Appendix E).37-39 Mean withdrawal is 
derived as the average of seven of the eight symptoms (range, 0-4), with the item “Desire 
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or Craving to Smoke” analyzed separately.40 Previous studies have shown this measure 
has good reliability and validity.37-39 The QSU is comprised of 37 statements indicating 
current cravings to smoke (e.g., “A cigarette would taste good right now.”, “I could 
control things better right now if I could smoke.”) (see Appendix F). 41, 42 The instrument 
is scored such that two factors are derived, with Factor 1 often described as a measure of 
the positive reinforcing effects of smoking and Factor 2 a measure of the negative 
reinforcing effects of smoking. Previous studies have indicated that it is a reliable and 
valid measure of smoking urges.42, 43   
 Participants were compensated for their time and for successfully abstaining prior 
to the experimental session.  Pregnant participants ended their participation after this 
session.  For non-pregnant women, this session was their first in a larger 14-visit study 
designed to test the acute effects of cigarettes with varying nicotine levels.  Data from 
later sessions completed by non-pregnant women have been reported elsewhere.44 
Statistical Method 
 Independent t-tests and Fisher’s exact tests were used to compare demographic 
and smoking characteristics between the two groups. 
 All topography measures were log-transformed to meet normal distribution 
requirements so that parametric tests could be used to compare the two groups.  Smoking 
topography measures were compared using independent t-tests.  To explore whether 
topography changes as a function of increasing gestational age, a Pearson product-
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moment correlation coefficient was computed to assess whether estimated gestational age 
(EGA) and any of the smoking topography parameters were related. 
 The five mCEQ subscales were compared between pregnant and non-pregnant 
smokers using independent t-tests.  CO boost, mean total MNWS score, MNWS item 
‘desire to smoke’, QSU Factor 1 and QSU Factor 2 were compared between the two 
groups and across time points using repeated measures analysis of variance, with time as 
the within-subjects factor and pregnancy status as the between-subject factor.  CO boost 
was also characterized and compared using area under the curve. To do so, trapezoids 
were constructed with the x- and y-axis coordinates for each data point and the combined 
area of the three trapezoids summed. 
 Significance for all tests was set at p < .05.   
RESULTS 
Participant Characteristics 
Seventeen pregnant and 91 non-pregnant female smokers completed the 
experimental session.   The two groups were remarkably similar on demographic and 
smoking characteristics.  On average, participants were 30 years old, Caucasian, had a 
high school education or less, and were unmarried (Table 1). Women in both groups had 
an average body mass index of 33, which falls in the overweight range.  One-third of 
participants were opioid-maintained.  Pregnant smokers were 24 weeks EGA on average.  
All but one of the smoking characteristics examined did not differ significantly between 
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groups.  At screening, both groups reported smoking approximately 14 CPD, with 
pregnant women reporting cutting down from smoking 22 CPD prior to pregnancy (a 
43% reduction). Women in both groups also tended to smoke high nicotine yield, non-
menthol cigarettes, had moderate levels of nicotine dependence, started smoking around 
15 years of age and had average urine cotinine levels of 850 ng/ml. The only significant 
difference between groups was on NMR, which was, as expected, significantly higher 
among pregnant smokers as compared to non-pregnant smokers (p = .01). 8, 9  
Smoking Topography  
There were no statistically significant differences in smoking topography between 
pregnant and non-pregnant women, with differences across parameters averaging less 
than 5% (Figure 1).  Within the pregnant smoker sample, there were no significant 
correlations between EGA and topography measures.   
CO boost was significantly higher in non-pregnant as compared to pregnant 
smokers (p < .05) and decreased in a parallel fashion in both groups over time (p < .001; 
Figure 2). Area under the curve analyses indicated CO boost was 24% higher among non-
pregnant as compared to pregnant smokers (p < .05).  
mCEQ 
 Of the five subscales, only the Satisfaction subscale was significantly different, 
with lower scores among pregnant women as compared to non-pregnant women (p < 
.001; Figure 3).  Although not significant, pregnant women also trended towards higher 
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scores on the Aversion subscale and lower scores on the Enjoyment of Respiratory Tract 
Sensations subscale as compared to non-pregnant women (ps = .06 and .07, respectively).   
MNWS 
There were no significant differences between groups on mean MNWS scores or 
on the MNWS item “Desire or Craving to Smoke”.  Both groups did report significant 
changes over time on these measures, with decreased scores 15 min after smoking the 
cigarette followed by increasing scores across subsequent time points (p < .001; Figure 4, 
top panel).  This U-shaped function is consistent with acute relief of withdrawal after 
smoking a cigarette.   
QSU 
There were significant differences between groups on both QSU Factor 1 and 
QSU Factor 2 scores.  While scores on both factors appeared equivalent in both groups 
prior to smoking a usual brand cigarette through the CReSS device, after smoking, 
pregnant women reported significantly lower positive and negative reinforcing effects of 
smoking as compared to non-pregnant smokers (ps < .001; Figure 4, bottom panel).  
Scores in both groups then increased in a parallel fashion across subsequent time points 
on both factors (ps < .001; Figure 4, bottom panel).   
 
 




 To our knowledge, this was the first study comparing the smoking topography of 
pregnant and non-pregnant smokers.  Despite reporting decreases in their CPD and 
experiencing increases in nicotine metabolism rate, there were no differences in smoking 
topography between pregnant and non-pregnant female smokers. Although no differences 
were observed on any topography parameters, pregnant smokers had a smaller CO boost, 
suggesting they may experience less toxicant exposure per cigarette.  This smaller CO 
boost may be explained by changes in the respiratory system during pregnancy that are a 
response to increased demand for oxygen for the fetus and the mother. 45 These 
adaptations are largely facilitated by hormonal and anatomical changes.  For example, 
progesterone has been shown to heighten central nervous system chemoreceptor 
sensitivity to CO2.  As another example, as the uterus expands, the diaphragm elevates 
and the subcostal angle (the upside-down ‘V’ shaped section below the sternum) widens. 
Together, these changes lead to a decreased residual volume (the air left in the lungs after 
an exhale) and increased inspiratory capacity (the amount that can be inhaled after 
normal expiration), thereby increasing overall tidal volume (the total amount of air in one 
inhale and one exhale combined).  Since there were no differences in smoking 
topography between groups in the present study, it suggests that pregnant smokers take in 
the same amount of cigarette smoke, including CO, from smoking one cigarette as non-
pregnant smokers.  However, because pregnant smokers have a larger tidal volume, more 
CO can be exhaled with every breath, leading to a smaller CO boost.  Observation of a 
 24   
 
 
smaller CO boost is also consistent with evidence from our group and others suggesting 
that CO levels associated with abstinence are lower in pregnant smokers compared to 
non-pregnant smokers.46, 47 In sum, it appears that pregnant smokers may experience less 
exposure to toxicants like CO after smoking, although not by way of changes in smoking 
topography. 
 Across self-report questionnaires, two overarching findings emerged.  The first 
was that both groups experienced similar levels of relief from withdrawal and craving 
after smoking, with consistent results from the mean total MNWS and the mCEQ 
Psychological Reward subscale (despite the title, four of the five items on this subscale 
ask about withdrawal symptoms also queried on the MNWS) regarding withdrawal and 
consistent results from the MNWS “Desire or Craving to Smoke” item and the mCEQ 
Craving Reduction subscale regarding craving.   The second overarching finding was that 
multiple self-report measures suggested that pregnant smokers do not find smoking as 
reinforcing (either positively or negatively) as non-pregnant smokers.  QSU Factor 1 and 
2 scale scores, measures of the positive and negative reinforcing effects of smoking, were 
lower among pregnant smokers, as were mCEQ Satisfaction subscale scores.  The 
observation of trends towards lower scores on mCEQ Enjoyment of Respiratory Tract 
Sensations subscale and higher scores on mCEQ Aversion subscale among pregnant 
smokers added to this overall picture of smoking being less reinforcing for this group.  It 
is possible that decreases in the overall enjoyment of cigarette smoking facilitates the 
substantial reductions most female smokers report during pregnancy and may also 
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explain why they do not engage in compensatory smoking following such dramatic 
reductions.   
It was surprising that baseline cotinine levels did not differ between pregnant and 
non-pregnant smokers.  While both groups reported smoking about the same number of 
CPD, NMR was 30% faster among pregnant smokers, suggesting that their cotinine 
levels should have been lower if they were smoking approximately the same number of 
CPD and given no differences in smoking topography.  This discrepancy suggests that 
there may still be some social pressure on pregnant smokers to underreport their level of 
smoking even if they are not seeking treatment and have declared they do not have 
intentions of quitting for at least another week.   
 The present data provide a unique opportunity to explore potential differences in 
exposure between the socioeconomically disadvantaged women who participated in the 
current study and general population smokers.  One prior study that collected smoking 
topography measures in general population male and female smokers (education level not 
specified) under conditions similar to the present study (i.e., same smoking topography 
device, following acute abstinence) reported that they had a total puff volume (average 
puff volume X average number of puffs) of 553 ml.31 In comparison, the 
socioeconomically disadvantaged pregnant and non-pregnant smokers in the current 
study had average total puff volumes of 782 ml and 808 ml, respectively, approximately 
30% higher. As previously described, socioeconomically disadvantaged women are 
known to be at increased risk for (1) smoking, (2) nicotine dependence, (3) smoking more 
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CPD, (4) smoking higher nicotine yield cigarettes and (5) continuing to smoke after 
becoming pregnant, all of which contribute to worse health outcomes in this population. 
31, 32 The present data suggest that how they smoke may also contribute to these poor 
outcomes.  
These findings should be considered in light of some limitations.  First, the 
pregnant sample in this study is relatively small.  However, previous studies with similar 
sample sizes have found differences in smoking topography.31, 48 Additionally, the control 
group was closely matched on a number of demographic and smoking characteristics 
which eliminated variability that may have made it more difficult to detect differences 
between the groups. Furthermore, the differences in topography measures between non-
pregnant and pregnant smokers were relatively small (< 5% on average), which does not 
suggest that the study was underpowered.  Another potential limitation involves 
collecting smoking topography data through the CReSS device in a laboratory setting.  
Research is inconsistent on whether smoking a cigarette in an artificial laboratory 
environment alters smoking behavior.49, 50 Even if smoking through the CReSS device is 
not perfectly representative of smoking in the natural environment, the fact that both 
groups smoked through these devices allows relative comparisons of their smoking 
topography to be made.   
This study has notable strengths and makes a contribution to the scientific 
literature. To our knowledge, it is the first study to capture a variety of variables during a 
single cigarette smoking bout among pregnant smokers.  Specifically, this study 
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documented (1) smoking topography of usual brand cigarettes, (2) changes in CO in the 
hour that followed smoking, and (3) subjective effects of this smoking bout.  Most 
noteworthy among these is smoking topography.  For the past 20 years, researchers have 
speculated about whether pregnant smokers engage in compensatory smoking.  This was 
the first study to directly address this question.  In addition, a large sample of non-
pregnant female smokers who did not differ from the pregnant smokers on important 
demographic or smoking characteristics was included for comparison.  More generally, 
the present study speaks to the importance of using a variety of approaches to research 
smoking during pregnancy.  The overwhelming majority of the research conducted to 
date has been randomized controlled trials testing interventions to promote cessation 
during pregnancy.  While this is understandable to some degree given the serious adverse 
consequences of smoking during pregnancy, a recent Cochrane Review found 72 such 
trials conducted over more than 30 years with more than 20,000 pregnant smokers and 
reported that these interventions have only produced an average 6% increase in 
abstinence compared to control conditions. 51 The present study underscores the 
importance of conducting laboratory and other types of studies to help better understand 
smoking during pregnancy, research that may lead to more efficacious treatments in the 
future.   
There are a number of future directions that could be explored.  First, in regards to 
studying smoking topography during pregnancy, future studies should replicate this study 
in different contexts.  For example, smoking topography can be measured using a 
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portable version of the CReSS device used in the present study that can be sent home 
with participants to record data across multiple smoking bouts in the participant’s normal 
smoking environment.  These studies would help validate the findings reported in this 
paper.  Additional studies are also needed to more firmly establish the relationship 
between CPD and biochemical markers of smoking during pregnancy.  A recent study by 
Denlinger and colleagues (2016) assessed non-pregnant smokers in a controlled, but not 
entirely artificial, environment (i.e., a hotel that permitted smoking) for 5 days.52  This 
study allowed researchers to precisely quantify how many CPD participants smoked and 
the levels of cotinine and other biomarkers that resulted.  A similar study with pregnant 
women could generate population estimates that could be used for research and clinical 
purposes.   
In summary, results of the present study suggest that the smoking topography of 
pregnant smokers does not differ from that of non-pregnant female smokers and that 
pregnant smokers find smoking less reinforcing. These changes in reinforcement may 
help pregnant smokers make the substantial reductions in CPD typically reported during 
pregnancy and may also protect them from engaging in compensatory smoking.  
FUNDING 
This project was supported by a Tobacco Centers of Regulatory Science (TCORS) award 
(P50DA036114) from the National Institute on Drug Abuse and Food and Drug 
Administration.   




1. U.S. Department of Health and Human Services. The health consequences of 
smoking: 50 years of progress. A report of the Surgeon General. Atlanta, GA: 
U.S. Department of Health and Human Services, Centers for Disease Control and 
Prevention, National Center for Chronic Disease Prevention and Health 
Promotion, Office on Smoking and Health. 2014. 
2. Coleman T, Cooper S, Thornton JG, et al. A randomized trial of nicotine-
replacement therapy patches in pregnancy. N Engl J Med. 2012; 366(9): 808–18. 
3. Heil SH, Higgins ST, Bernstein IM, et al. Effects of voucher-based incentives on 
abstinence from cigarette smoking and fetal growth among pregnant women. 
Addiction. 2008;103(6): 1009–1018.  
4. Higgins ST, Heil SH, Solomon LJ, et al. A pilot study on voucher-based 
incentives to promote abstinence from cigarette smoking during pregnancy and 
postpartum. Nicotine Tob Res. 2004; 6(6): 1015–1020.  
5. Rigotti NA, Park ER, Regan S, et al. Efficacy of telephone counseling for 
pregnant smokers: a randomized controlled trial. Obstet Gynecol. 2006; 108(1): 
83–92.  
6. Ussher M, Lewis S, Aveyard P, et al. The London Exercise and Pregnant smokers 
(LEAP) trial: A randomised controlled trial of physical activity for smoking 
cessation in pregnancy with an economic evaluation. Health Technol Assess. 
2015; 19(84): 1–136.  
 30   
 
 
7. Heil SH, Herrmann ES, Badger GJ, et al. Examining the timing of changes in 
cigarette smoking upon learning of pregnancy. Prev Med. 2014; 68: 58–61.  
8. Bowker K, Lewis S, Coleman T, Cooper S. Changes in the rate of nicotine 
metabolism across pregnancy: a longitudinal study. Addiction. 2015; 110(11): 
1827. 
9. Dempsey D, Jacob P, Benowitz NL. Accelerated metabolism of nicotine and 
cotinine in pregnant smokers. J Pharmacol Exp Ther. 2002; 310(2): 594-598. 
10. Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces 
smoking. Nature. 1999; 393: 750. 
11. Graham H, Flemming K, Fox D, Heirs M, Sowden A. Cutting down: insights 
from qualitative studies of smoking in pregnancy. Health Soc Care Community. 
2014; 2(3): 259-267. 
12. Heil SH, Solomon LJ, Skelly JM, Bernstein IM, Higgins ST. Correspondence 
between self-reported and biochemical measures of cigarette smoking in pregnant 
women. Oral presentation at the 77th meeting of the College on Problems of Drug 
Dependence, Phoenix, AZ. 2015. 
13. Boyd NR, Windsor RA, Perkins LL, Lowe JB. Quality of measurement of 
smoking status by self-report and saliva cotinine among pregnant women. Matern 
Child Health J. 1998; 2(2): 77–83. 
14. Ellard GA, Johnstone FD, Prescott RJ, Ji-Xian W, Jian-Hua M. Smoking during 
pregnancy: the dose dependence of birthweight deficits. Br J Obstet Gynaecol. 
1996; 103(8): 806-813. 
 31   
 
 
15. Klebanoff MA, Levine RJ, Clemens JD, DerSimonian R, Wilkins DG. Serum 
cotinine concentration and self-reported smoking during pregnancy. Am J 
Epidemiol. 1998; 148(3): 259–262. 
16. Pickett KE, Rathouz PJ, Kasza K, Wakschlag LS, Wright R. Self-reported 
smoking, cotinine levels, and patterns of smoking in pregnancy. Paediatr Perinat 
Epidemiol. 2005; 19(5): 368-376. 
17. Dukic VM, Niessner M, Benowitz N, Hans S, Wakschlag L. Modelling the 
relationship of cotinine and self-reported measures of maternal smoking during 
pregnancy: a deterministic approach. Nicotine Tob Res. 2007; 9(4): 453-465. 
18. Lindqvist R, Lendahls L, Tollbom O, Aberg H, Hakansson A. Smoking during 
pregnancy: Comparison of self-report and cotinine levels in 496 women. Acta 
Obstet Gynecol Scand. 2002; 81(3): 240-244. 
19. Benowitz NL, Jacob P, Kozlowski LT, Yu L. Influence of smoking fewer 
cigarettes on exposure to tar, nicotine, and carbon monoxide. N Engl J Med. 
1986; 315(21): 1310–131. 
20. Jarvis MJ, Giovino GA, O’Connor RJ, Kozlowski LT, Bernert JT. Variation in 
nicotine intake among U.S. cigarette smokers during the past 25 years: Evidence 
from NHANES surveys. Nicotine Tob Res. 2014; 16(12): 1620–1628.  
21. Dempsey D, Tutka P, Jacob P, Allen F, Schoedel K, Tyndale RF, Benowitz NL. 
Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.  
Clin Pharmacol Ther. 2004; 76(1): 64-72. 
 32   
 
 
22. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test 
for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. 
Br J Addict. 1991; 86(9): 1119–1127. 
23. Pomerleau CS, Majchrzak MJ, Pomerleau OF. Nicotine dependence and the 
Fagerström Tolerance Questionnaire: A brief review. J Subst Abuse. 1989; 1(4): 
471–477. 
24. Pomerleau CS, Carton SM, Lutzke ML, Flessland KA, Pomerleau OF. Reliability 
of the Fagerstrӧm Tolerance Questionnaire and the Fagerstrӧm Test for Nicotine 
Dependence. Addict Behav. 1994; 19(1): 33–39. 
25. Chilcoat HD. An overview of the emergence of disparities in smoking prevalence, 
cessation, and adverse consequences among women. Drug Alcohol Depend. 2009; 
104: S17-S23. 
26. Higgins ST, Heil SH, Badger GJ, Skelly JM, Solomon LJ, Bernstein IM. 
Educational disadvantage and cigarette smoking during pregnancy. Drug Alcohol 
Depend. 2009; 104 Suppl 1: S100–105.  
27. Concheiro M, Jones HE, Johnson RE, Choo R, Huestis MA. Preliminary 
buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and 
sweat during treatment of opioid-dependent pregnant women.  Ther Drug Monit. 
2011; 33(5): 619-626.  
28. Wolff K, Boys A, Rostami-Hodjegan, Hay A, Raistrick D. Changes to methadone 
clearance during pregnancy. Eur J Clin Pharmacol. 2005; 61(10): 763-768. 
 33   
 
 
29. Johnson MW, Bickel WK, Kirshenbaum AP. Substitutes for tobacco smoking: a 
behavioral economic analysis of nicotine gum, denicotinized cigarettes, and 
nicotine containing cigarettes. Drug Alcohol Depend. 2004; 74: 253-264.  
30. Tidey JW, O’Neill SE, Higgins ST. Effects of abstinence on cigarette smoking 
among outpatients with schizophrenia. Exp Clin Psychopharmacol. 1999; 7: 347-
353. 
31. Blank MD, Disharoon S, Eissenberg T. Comparison of methods for measurement 
of smoking behavior: mouthpiece-based computerized devices versus direct 
observation. Nicotine Tob Res. 2009; 11(7): 896–903.  
32. Lee EM, Malson JL, Waters AJ, Moolchan ET, Pickworth WB. Smoking 
topography: Reliability and validity in dependent smokers. Nicotine Tob Res. 
2003; 5(5): 673-679. 
33. Westman E, Levin E, Rose J. Smoking while wearing the nicotine patch: Is 
smoking satisfying or harmful? Clin Res. 1992; 40: 871-877. 
34. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. 
Confirmatory factor analyses and reliability of the modified cigarette evaluation 
questionnaire. Addict Behav. 2007; 32(5): 912-923. 
35. Strasser AA, Ashare RL, Kozlowski LT, Pickworth WB. The effect of filter 
blocking and smoking topography on carbon monoxide levels in smokers. 
Pharmacol Biochem Behav. 2005; 82(2): 320-329. 
 34   
 
 
36. Zacny JP, Stitzer ML, Brown FJ, Yingling JE, Griffiths RR. Human cigarette 
smoking: effects of puff and inhalation parameters on smoke exposure. J 
Pharmacol Exp Ther. 1987; 240(2): 554- 564. 
37. Hughes, JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen 
Psychiatry. 1986; 43(3): 289–294. 
38. Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW. Symptoms of tobacco 
withdrawal. A replication and extension. Arch Gen Psychiatry. 1991; 48(1): 52–
59. 
39. Hughes JR. Tobacco withdrawal in self-quitters. J Consult Clin Psychol. 1992; 
60(5): 689–697. 
40. Hughes J, Hatsukami DK. Errors in using tobacco withdrawal scale. Tob Control. 
1998; 7: 92-93. 
41. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of 
smoking urges (QSU-brief) in a laboratory and clinical settings. Nicotine Tob 
Res. 2001; 3: 7-17. 
42. Tiffany ST, Drobes DJ. The development and initial validation of a questionnaire 
on smoking urges. Br J Addict. 1991; 86: 1467-1476. 
43. Toll BA, Katalua NA, McKee SA. Investigating the factor structure of the 
Questionnaire on Smoking Urges – Brief (QSU-Brief). Addict Behav. 2006; 
31(7): 1231-1239. 
44. Higgins ST, Heil SH, Sigmon SC, et al. Response to Varying the Nicotine 
Content of Cigarettes in Vulnerable Populations. Paper to be presented at: 2016 
 35   
 
 
Tobacco Centers on Regulatory Science Grantee Meeting; November 7-8; 
Bethesda, MD.  
45. Monga M, Mastrobattista JM. Maternal Cardiovascular, Respiratory, and Renal 
Adaptation to Pregnancy. In: Creasy and Resnik’s Maternal-Fetal Medicine: 
Principles and Practice. 7th ed. Philadelphia, PA: Elsevier/Saunders; 2014. 
46. Higgins ST, Heil SH, Badger GJ, et al.  Biochemical verification of smoking 
status in pregnant and recently postpartum women. Exp Clin Psychopharmacol. 
2007; 15(1): 58-66.  
47. Bailey BA. Using expired air carbon monoxide to determine smoking status 
during pregnancy: preliminary identification of an appropriately sensitive and 
specific cut-point. Addict Behav. 2013; 38(10): 2547-2550. 
48. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. Cigarette smoking topography 
in smokers with schizophrenia and matched non-psychiatric controls. Drug 
Alcohol Depend. 2005; 80(2): 259-265. 
49. Ossip-Klein DJ, Martin JE, Lomax BD, Prue DM, Davis CJ.  Assessment of 
smoking topography generalization across laboratory, clinical, and naturalistic 
settings.  Addict Behav. 1983; 8(1): 11-17. 
50. Hatsukami D, Morgan SF, Pickens RW, Hughes JR. Smoking topography in a 
nonlaboratory environment. Int J Addict. 1987; 22(8): 719-725. 
51. Lumley J, Chamberlaian C, Doswell T, et al. Interventions for promoting smoking 
cessation during pregnancy. Cochrane Database Syst Rev. 2009 Jul 8; CD001055. 
 36   
 
 
52. Denlinger RL, Smith TT, Murphy S, et al. Characterizing biomarkers of nicotine 
exposure when smoking very low nicotine content cigarettes in a controlled 
access environment. Tob Reg Science. 2016; 2: 186-203. 
  
 37   
 
 








Demographics    
           Age 30.4 ± 4.9 30.2 ± 7.0 .89 
           % White 94 96 .55 
           % High school graduate or less 59 52 .56 
           % Never married 71 57 .62 
           Body mass index 34.8 ± 22.2 31.1 ± 6.6 .18 
           % Opioid-dependent 41 32 .58 
           Estimated weeks gestational age  24.1 ± 9.5  N/A  
Smoking Characteristics    
           Pre-pregnancy cigarettes per day 22.4  ± 8.5 N/A  
           Cigarettes per day at screening  12.9 ± 5.8 15.3 ± 5.7  .12 
           Nicotine yield for usual brand cigarette 1.0 ± 0.4 1.1 ± 0.2 .59 
           % Menthol   25 24 .98 
           Fagerström Test for Nicotine Dependence 4.1 ± 0.5 4.6 ± 2.2 .35 
           Age first started smoking 14.7 ± 3.5 15.6 ± 3.0 .26 
Biochemical Measures    
           Urine cotinine (ng/ml) 785.4 ± 546.2 920.5 ± 488.7 .27 
           Nicotine metabolite ratio 0.62 ± 0.29 0.46 ± 0.35 .01 
Note: Values in the table are reported as means ± standard deviations unless otherwise 
noted. Nicotine yield values come from the Federal Trade Commission’s Tar, Nicotine 
and Carbon Monoxide Report from 1999-2005.  Nicotine metabolite ratio was log-












Figure 1. Mean ± SEM for smoking topography parameters for pregnant and non-
pregnant smokers as measured by the CReSS Desktop Smoking Topography device.  
There were no significant differences between groups on any parameter.   
Figure 2. Mean ± SD CO boost at 15, 30, 45 and 60 minutes after pregnant and non-
pregnant smokers smoked one usual brand cigarette. There were significant effects of 
group and time (ps < .05), but no interaction. 
Figure 3. Mean ± SEM Modified Cigarette Evaluation Questionnaire subscale scores 
immediately after smoking usual brand cigarettes in pregnant and non-pregnant smokers.  
An asterisk (*) indicates a significant effect of group (p < .001). 
Figure 4. Mean ± SEM scores for the Minnesota Nicotine Withdrawal Scale (MNWS) 
total score (top left panel), MNWS item ‘desire or craving to smoke’ (top right panel), 
and Questionnaire of Smoking Urges (QSU) Factor 1 and QSU Factor 2 (bottom left and 
right panels, respectively) before and 15, 30, 45 and 60 minutes after pregnant and non-
pregnant smokers smoked one usual brand cigarette. There was a significant effect of 
time on all measures. There was also a significant effect of group for QSU Factors 1 and 
























































































































































Abrahamsson, A., Springett, J., Karlsson, L., & Ottosson, T. (2005). Making sense of the 
challenge of smoking cessation during pregnancy: a phenomenographic approach. Health 
Education Research, 20(3), 367–378. 
  
Adams, E. K., Melvin, C. L., Raskind-Hood, C., Joski, P. J., & Galactionova, E. (2011). Infant 
delivery costs related to maternal smoking: an update. Nicotine & Tobacco Research, 
13(8), 627–637.  
 
Aliyu, M. H., Lynch, O., Wilson, R. E., Alio, A. P., Kristensen, S., Marty, P. J.,  Salihu, H. M. 
(2011). Association between tobacco use in pregnancy and placenta-associated 
syndromes: a population-based study. Archives of Gynecology and Obstetrics, 283(4), 
729–734.  
 
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders: 
DSM-IV-TR. Washington, DC: American Psychiatric Association. 
 
Arnold, C. L., Davis, T. C., Berkel, H. J., Jackson, R. H., Nandy, I., & London, S. (2001). 
Smoking status, reading level, and knowledge of tobacco effects among low-income 
pregnant women. Preventive Medicine, 32(4), 313–320.  
 
Bailey, B. A. (2013). Using expired air carbon monoxide to determine smoking status during 
pregnancy: preliminary identification of an appropriately sensitive and specific cut-point. 
Addictive Behaviors, 38(10), 2547-2550. 
 
Beck, A. T., Ward, C., & Mendelson, M. (1961). Beck depression inventory (BDI). Archives of 
General Psychiatry, 4, 561-571. 
 
Benowitz, N. L., Jacob, P., Kozlowski, L. T., & Yu, L. (1986). Influence of smoking fewer 
cigarettes on exposure to tar, nicotine, and carbon monoxide. The New England Journal 
of Medicine, 315(21), 1310–131. 
 
Blank, M. D., Disharoon, S., & Eissenberg, T. (2009). Comparison of methods for measurement 
of smoking behavior: mouthpiece-based computerized devices versus direct observation. 
Nicotine and Tobacco Research, 11(7), 896–903.  
 
Bowker, K., Lewis, S., Coleman, T., & Cooper, S. (2015). Changes in the rate of nicotine 
metabolism across pregnancy: a longitudinal study. Addiction, 110(11), 1827–1832.  
 
Boyd, N. R., Windsor, R. A., Perkins, L. L., & Lowe, J. B. (1998). Quality of measurement of 
smoking status by self-report and saliva cotinine among pregnant women. Maternal and 
Child Health Journal, 2(2), 77–83. 
 
Bruin, J. E., Gerstein, H. C., & Holloway, A. C. (2010). Long-term consequences of fetal and 
neonatal nicotine exposure: A critical review. Toxicological Sciences, 116(2), 364–374.  
 
 44   
 
 
Cappelleri, J. C., Bushmakin, A. G., Baker, C. L., Merikle, E., Olufade, A. O., & Gilbert, D. G. 
(2007). Confirmatory factor analyses and reliability of the modified cigarette evaluation 
questionnaire. Addictive Behaviors, 32(5), 912–923. 
 
Chase, H. W., MacKillop, J., & Hogarth, L. (2012). Isolating behavioural economic indices of 
demand in relation to nicotine dependence. Psychopharmacology, 226(2), 371–380.  
 
Chilcoat, H. D. (2009). An overview of the emergence of disparities in smoking prevalence, 
cessation, and adverse consequences among women. Drug and Alcohol Dependence, 104, 
S17-S23. 
 
Cohen, G., Jeffery, H., Lagercrantz, H., & Katz-Salamon, M. (2010). Long-term reprogramming 
of cardiovascular function in infants of active smokers. Hypertension, 55(3), 722–728.  
 
Coleman, T., Cooper, S., Thornton, J. G., Grainge, M. J., Watts, K., Britton, J., & Lewis, S. 
(2012). A randomized trial of nicotine-replacement therapy patches in pregnancy. The 
New England Journal of Medicine, 366(9), 808–18. 
 
Concheiro, M., Jones, H. E., Johnson, R. E., Choo, R., Huestis, M. A. (2011). Preliminary 
buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat 
during treatment of opioid-dependent pregnant women.  Therapeutic Drug Monitoring, 
33(5), 619-626.  
 
Connor Gorber, S., Schofield-Hurwitz, S., Hardt, J., Levasseur, G., & Tremblay, M.  (2009). The 
accuracy of self-reported smoking: a systematic review of the relationship between self-
reported and cotinine assessed smoking status. Nicotine and Tobacco Research, 11(1), 
12-24. 
 
Cox, L. S., Tiffany, S. T., Christien, A. G. (2001). Evaluation of the brief questionnaire of 
smoking urges (QSU-brief) in a laboratory and clinical settings. Nicotine and Tobacco 
Research, 3, 7-17. 
 
Dempsey, D., Jacob, P., & Benowitz, N. L. (2002). Accelerated metabolism of nicotine and 
cotinine in pregnant smokers.  Journal of Pharmacological Experimental Therapy, 
310(2), 594-598. 
 
Dempsey, D., Tutka, P., Jacob, P., Allen, F., Shoedel, K., Tyndale, R. F., & Benowitz, N. L. 
(2004).  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic 
activity.  Clinical Pharmacology and Therapeutics, 76(1), 64-72.  
 
Denlinger, R. L., Smith, T. T., Murphy, S., Koopmeiners, J., Benowitz, N. L., Hatsukami, D. K. 
… Donny, E. C. (2016). Characterizing biomarkers of nicotine exposure when smoking 
very low nicotine content cigarettes in a controlled access environment. Tobacco 
Regulatory Science, 9, 186-203. 
 
 45   
 
 
Dietz, P. M., England, L. J., Shapiro-Mendoza, C. K., Tong, V. T., Farr, S. L., & Callaghan, W. 
M. (2010). Infant morbidity and mortality attributable to prenatal smoking in the U.S. 
American Journal of Preventive Medicine, 39(1), 45–52. 
 
Dornelas, E. A., Magnavita, J., Beazoglou, T., Fischer, E. H., Oncken, C., Lando, H., … 
Gregonis, E. (2006). Efficacy and cost-effectiveness of a clinic-based counseling 
intervention tested in an ethnically diverse sample of pregnant smokers. Patient 
Education and Counseling, 64(1-3), 342–349.  
 
Dukic, V. M., Niessner, M., Benowitz, N., Hans, S., & Wakschlag, L. (2007). Modeling the 
relationship of cotinine and self-reported measures of maternal smoking during 
pregnancy: a deterministic approach. Nicotine and Tobacco Research, 9(4), 453–465.  
 
Eissenberg, T., Adams, C., Riggins, E. C., & Likness, M. (1999). Smokers’ sex and the effects of 
tobacco cigarettes: subject-rated and physiological measures. Nicotine and Tobacco 
Research 1(4), 317-324.  
 
Ellard, G. A., Johnstone, F. D., Prescott, R. J., Ji-Xian, W., & Jian-Hua, M. (1996). Smoking 
during pregnancy: the dose dependence of birthweight deficits. British Journal of 
Obstetrics and Gynaecology, 103(8), 806-813. 
 
Few, L. R., Acker, J., Murphy, C., & MacKillop, J. (2012). Temporal stability of a cigarette 
purchase task. Nicotine and Tobacco Research, 14(6), 761–765.  
 
Graham, H., Flemming, K., Fox, D., Heirs, M., & Sowden, A. (2014). Cutting down: insights 
from qualitative studies of smoking in pregnancy. Health and Social Care in the 
Community, 2(3), 259-267. 
 
Hackshaw, A., Rodeck, C., & Boniface, S. (2011).  Maternal smoking in pregnancy and birth 
defects: a systematic review based on 173,687 malformed cases and 11.7 million 
controls.  Human Reproduction Update, 17(5), 589–604.  
 
Hatsukami, D., Morgan, S. F., Pickens, R. W., & Hughes, J. R. Smoking topography in a 
nonlaboratory environment. International Journal of the Addictions, 22(8), 719-725. 
 
Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerström 
Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. 
British Journal of Addiction, 86(9), 1119–1127. 
 
Heil, S. H., Higgins, S. T., Bernstein, I. M., Solomon, L. J., Rogers, R. E., Thomas, C. S., … 
Lynch, M. E. (2008). Effects of voucher-based incentives on abstinence from cigarette 
smoking and fetal growth among pregnant women, Addiction, 103(6), 1009–1018.  
 
Heil, S. H., Herrmann, E. S., Badger, G. J., Solomon, L. J., Bernstein, I. M., & Higgins, S. T. 
(2014). Examining the timing of changes in cigarette smoking upon learning of 
pregnancy. Preventive Medicine, 68, 58–61.  
 
 46   
 
 
Heil, S. H., Solomon, L. J., Skelly, J. M., Bernstein, I. M., & Higgins, S. T. (2015, June). 
Correspondence between self-reported and biochemical measures of cigarette smoking in 
pregnant women. Oral presentation at the 77th meeting of the College on Problems of 
Drug Dependence, Phoenix, AZ.  
 
Heinonen, K., Räikkönen, K., Pesonen, A.-K., Andersson, S., Kajantie, E., Eriksson, J. G., & 
Lano, A. (2011). Longitudinal study of smoking cessation before pregnancy and 
children’s cognitive abilities at 56 months of age. Early Human Development, 87(5), 
353–359. 
  
Higgins, S. T., Heil, S. H., Solomon, L. J., Bernstein, I. M., Lussier, J. P., Abel, R. L., … E., 
Badger, G. J. (2004). A pilot study on voucher-based incentives to promote abstinence 
from cigarette smoking during pregnancy and postpartum. Nicotine and Tobacco 
Research, 6(6), 1015–1020. 
 
Higgins, S. T., Heil, S. H., Badger, G. J., Mongeon, J. A., Solomon, L. J., McHale, L., & 
Bernstein, I. M. (2007). Biochemical verification of smoking status in pregnant and 
recently postpartum women.  Experimental and Clinical Psychopharmacology, 15(1), 58-
66. 
 
Higgins, S. T., Heil, S. H., Badger, G. J., Skelly, J. M., Solomon, L. J., & Bernstein, I. M. (2009). 
Educational disadvantage and cigarette smoking during pregnancy. Drug and Alcohol 
Dependence, 104 Suppl 1, S100–105.  
 
Higgins, S. T., Washio, Y., Lopez, A. A., Heil, S. H., Solomon, L. J., Lynch, M. E., … Bernstein, 
I. M. (2014). Examining two different schedules of financial incentives for smoking 
cessation among pregnant women. Preventive Medicine, 68, 51–57.  
 
Higgins, S. T., Heil, S. H., Sigmon, S. C., Tidey, J. W., Gaalema, D. E., Stitzer, M. L., … Pacek, 
L. R. (2016, November). Response to Varying the Nicotine Content of Cigarettes in 
Vulnerable Populations. Oral presentation at the annual Tobacco Centers on Regulatory 
Science Grantee Meeting, Bethesda, MD. 
 
Hughes, J. R., & Hatsukami, D. (1986). Signs and symptoms of tobacco withdrawal. Archives of 
General Psychiatry, 43(3), 289–294. 
 
Hughes, J. R., Gust, S. W., Skoog, K., Keenan, R. M., & Fenwick, J. W. (1991). Symptoms of 
tobacco withdrawal. A replication and extension. Archives of General Psychiatry, 48(1), 
52–59. 
 
Hughes, J. R. (1992). Tobacco withdrawal in self-quitters. Journal of Consulting and Clinical 
Psychology, 60(5), 689–697. 
 
Hughes, J. R., & Hatuskami, D. (1998). Errors in using tobacco withdrawal scale. Tobacco 
Control, 7, 92-93. 
 
 47   
 
 
Jarvis, M. J., Tunstall-Pedoe, H., Feyerabend, C., Vesey, C., & Saloojee, Y. (1987). Comparison 
of tests used to distinguish smokers from nonsmokers.  American Journal of Public 
Health, 77(11), 1435-1438. 
 
Jarvis, M. J., Giovino, G. A., O’Connor, R. J., Kozlowski, L. T., & Bernert, J. T. (2014). 
Variation in nicotine intake among U.S. cigarette smokers during the past 25 years: 
Evidence from NHANES surveys. Nicotine and Tobacco Research, 16(12), 1620–1628.  
 
Johnson, M. W., Bickel, W. K., & Kirshenbaum, A. P. (2004). Substitutes for tobacco smoking: a 
behavioral economic analysis of nicotine gum, denicotinized cigarettes, and nicotine 
containing cigarettes. Drug and Alcohol Dependence, 74, 253-264.  
 
Klebanoff, M. A., Levine, R. J., Clemens, J. D., DerSimonian, R., & Wilkins, D. G. (1998). 
Serum cotinine concentration and self-reported smoking during pregnancy. American 
Journal of Epidemiology, 148(3), 259–262. 
 
Lee, E. M., Malson, J. L., Waters, A. J., Moolchan, E. T., & Pickworth, W. B. (2003). Smoking 
topography: Reliability and validity in dependent smokers. Nicotine and Tobacco 
Research, 5(5), 673-679. 
 
Levi, M., Dempsey, D. A., Benowitz, N. L., & Sheiner, L. B. (2007). Prediction methods for 
nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II: Model 
application.  Journal of Pharmacokinetics and Pharmacodynamics, 34(1), 23-34.  
 
Lindqvist, R., Lendahls, L., Tollbom, O., Aberg, H., & Håkansson, A. (2002). Smoking during 
pregnancy: Comparison of self-reports and cotinine levels in 496 women. Acta 
Obstetricia Et Gynecologica Scandinavica, 81(3), 240–244. 
 
Lumley, J., Chamberlain, C., Doswell, T., Oliver, S., Oakley, L., & Watson, L. (2009). 
Interventions for promoting smoking cessation during pregnancy. Cochrane Database of 
Systemic Review, 8(3). 
 
MacKillop, J., Murphy, J. G., Ray, L. A., Eisenberg, D. T. A., Lisman, S. A., Lum, J. K., & 
Wilson, D. S. (2008). Further validation of a cigarette purchase task for assessing the 
relative reinforcing efficacy of nicotine in college smokers. Experimental and Clinical 
Psychopharmacology, 16(1), 57–65.  
 
Magura, S. & Kang, S. Y. (1996). Validity of self-reported drug use in high risk populations: A 
meta-analytical review. Substance Use and Misuse, 31(9), 1131-1153. 
 
Monga, M., Mastrobattista, J. M. (2014). Maternal Cardiovascular, Respiratory, and Renal 
Adaptation to Pregnancy. In R. Resnik & R. K. Creasey (Eds.), Creasy and Resnik’s 
Maternal-Fetal Medicine: Principles and Practice, 7th ed.. Philademphia, PA: 
Elsevier/Saunders.  
 
 48   
 
 
Moylan, S., Gustavson, K., Øverland, S., Karevold, E. B., Jacka, F. N., Pasco, J. A., & Berk, M. 
(2015). The impact of maternal smoking during pregnancy on depressive and anxiety 
behaviors in children: The Norwegian mother and child cohort study. BMC Medicine, 13.  
 
National Institute on Drug Abuse. (2012). Principles of drug addiction treatment (NIH 
Publication No. 12-4180). Washington, DC: U.S. Government Printing Office. 
 
Norman, S. B., Cissell, S. H., Means-Christensen, A. J., & Stein, M. B. (2006). Development and 
validation of an Overall Anxiety Severity And Impairment Scale (OASIS). Depression 
and Anxiety, 23(4), 245–249. 
 
Ossip-Klein, D. J., Martin, J. E., Lomax, B. D., Prue, D. M., & Davis, C. J. (1983). Assessment of 
smoking topography generalization across laboratory, clinical, and naturalistic settings. 
Addictive Behaviors, 8(1), 11-17. 
 
Pianezza, M. L., Sellers, E. M., Tyndale, R. F. (1999). Nicotine metabolism defect reduces 
smoking. Nature, 393, 750. 
 
Pickett, K. E., Rathouz, P. J., Kasza, K., Wakschlag, L. S., & Wright, R. (2005). Self-reported 
smoking, cotinine levels, and patterns of smoking in pregnancy. Paediatric and Perinatal 
Epidemiology, 19(5), 368-376. 
 
Pineles, B. L., Park, E., & Samet, J. M. (2014). Systematic review and meta-analysis of 
miscarriage and maternal exposure to tobacco smoke during pregnancy. American 
Journal of Epidemiology, 179(7), 807–823.  
 
Piper, M. E., McCarthy, D. E., Bolt, D. M., Smith, S. S., Lerman, C., Benowitz, N., … Baker, T. 
B. (2008). Assessing dimensions of nicotine dependence: an evaluation of the Nicotine 
Dependence Syndrome Scale (NDSS) and the Wisconsin Inventory of Smoking 
Dependence Motives (WISDM). Nicotine and Tobacco Research, 10(6), 1009–1020.  
 
Pollak, K. I., Oncken, C. A., Lipkus, I. M., Lyna, P., Swamy, G. K., Pletsch, P. K., …  Myers, E. 
R. (2007). Nicotine replacement and behavioral therapy for smoking cessation in 
pregnancy. American Journal of Preventive Medicine, 33(4), 297–305.  
 
Pomerleau, C. S., Majchrzak, M. J., & Pomerleau, O. F. (1989). Nicotine dependence and the 
Fagerström Tolerance Questionnaire: A brief review. Journal of Substance Abuse, 1(4), 
471–477. 
 
Pomerleau, C. S., Carton, S. M., Lutzke, M. L., Flessland, K. A., & Pomerleau, O. F. (1994). 
Reliability of the Fagerstrom Tolerance Questionnaire and the Fagerstrom Test for 
Nicotine Dependence. Addictive Behaviors, 19(1), 33–39. 
 
Rigotti, N. A., Park, E. R., Regan, S., Chang, Y., Perry, K., Loudin, B., & Quinn, V. (2006). 
Efficacy of telephone counseling for pregnant smokers: a randomized controlled trial. 
Obstetrics and Gynecology, 108(1), 83–92.  
 
 49   
 
 
Russell, T., Crawford, M., & Woodby, L. (2004). Measurements for active cigarette smoke 
exposure in prevalence and cessation studies: why simply asking pregnant women isn’t 
enough.  Nicotine and Tobacco Research, 6(2), 141-151. 
 
Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., … Dunbar, G. 
C. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): The 
development and validation of a structured diagnostic psychiatric interview for DSM-IV 
and ICD-10. The Journal of Clinical Psychiatry, 59(20), 22–33. 
 
Smith, S. S., Piper, M. E., Bolt, D. M., Fiore, M. C., Wetter, D. W., Cinciripini, P. M., & Baker, 
T. B. (2010). Development of the Brief Wisconsin Inventory of Smoking Dependence 
Motives. Nicotine and Tobacco Research, 12(5), 489–499. 
 
Solomon, L., & Quinn, V. (2004). Spontaneous quitting: Self-initiated smoking cessation in early 
pregnancy. Nicotine and Tobacco Research, 6(2), S203-S216. 
 
Strasser, A. A., Ashare, R. L., Kozlowski, L. T., Pickworth, W. B. (2005). The effect of filter 
blocking and smoking topography on carbon monoxide levels in smokers. Pharmacology 
Biochemistry and Behavior, 82(2), 320-329. 
 
Strasser, A. A., Malaiyandi, V., Hoffmann, E., Tyndale, R. F., & Lerman, C. (2007). An 
association of CYP2A6 genotype and smoking topography. Nicotine and Tobacco 
Research, 9(4), 511-518. 
 
Substance Abuse and Mental Health Services Administration. (2010). Results from the 2009 
National Survey on Drug Use and Health: Volume 1. Summary of national findings (HHS 
Publication No. SMA 10-4856 Findings). Rockville, MD. 
 
Tidey, J. W., O’Neill, S. E., & Higgins, S. T. (1999). Effects of abstinence on cigarette smoking 
among outpatients with schizophrenia. Experimental and Clinical Psychopharmacology, 
7, 347-353. 
 
Tidey, J. W., Rohsenow, D. J., Kaplan, G. B., & Swift, R. M. (2005). Cigarette smoking 
topography in smokers with schizophrenia and matches to non-psychiatric controls. Drug 
and Alcohol Dependence, 80(2), 259-265.  
 
Tiffany, S. T., & Drobes, D. J. (1991). The development and initial validation of a questionnaire 
on smoking urges. British Journal of Addiction, 86, 1467-1476. 
 
Toll, B. A., Katulak, N. A., & McKee, S. A. (2006). Investigating the factor structure of the 
Questionnaire on Smoking Urges-Brief (QSU-Brief). Addictive Behaviors, 31(7), 1231–
1239.  
 
U.S. Department of Health and Human Services. (2014). The health consequences of smoking: 50 
years of progress. A report of the surgeon general. Atlanta, GA: U.S. Department of 
 50   
 
 
Health and Human Services, Centers for Disease Control and Prevention, National Center 
for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 
Ussher, M., Lewis, S., Aveyard, P., Manyonda, I., West, R., Lewis, B., … Coleman, T. (2015). 
The London Exercise And Pregnant smokers (LEAP) trial: A randomised controlled trial 
of physical activity for smoking cessation in pregnancy with an economic evaluation. 
Health Technology Assessment, 19(84), 1–136.  
Wigginton, B., & Lee, C. (2013). Stigma and hostility towards pregnant smokers: Does 
individuating information reduce the effect? Psychology & Health, 28(8), 862–873. 
Westman, E., Levin, E., & Rose, J. (1992). Smoking while wearing the nicotine patch: Is smoking 
satisfying or harmful? Clinical Research, 40, 871-877. 
Wolff, K., Boys, A., Rostami-Hodjegan, Hay, A., Raistrick, D. (2005) Changes to methadone 
clearance during pregnancy. European Journal of Clinical Pharmacology, 61(10), 763-
768. 
Zacny, J. P., Stitzer, M. L., Brown, F. J., Yingling, J. E., Griffiths, R. R. (1987). Human cigarette 
smoking: effects of puff and inhalation parameters on smoke exposure. Journal of 




















Fagerstrӧm Test for Nicotine Dependence 
Description: A 6-item measure of intensity of nicotine dependence. Yes/no items are scored 0 or 
1 and multiple choice items are scored from 0 to 3.  Total scores are calculated by summing the 
score of all items and can range from 0-10. Higher scores indicate greater nicotine dependence. 
1. How soon after you wake up do you smoke your first 
cigarette? 
 0-5 minutes 
 6-30 minutes 
 31-60 minutes 
 More than 60 minutes 
2. Do you find it difficult to refrain from smoking in 
places where it is forbidden (such as in church, at the 
library, theater or doctor’s office)? 
 Yes 
 No 
3. Which cigarette would you hate most to give up? 
 The first one in the 
morning 
 Any other 
4. How many cigarettes a day do you smoke? 
 10 or less 
 11-20 
 21-30 
 31 or more 
5. Do you smoke more frequently during the first hours 
after waking than during the rest of the day? 
 Yes 
 No 
6. Do you smoke when you are so ill that you are in 









CReSS Desktop Smoking Topography Device 
Description: The CReSS device is an 8” X 6” X 5” console with two tubes connected to the front 
(Panel A).  The tubes extend about three feet and connect to a mouthpiece which holds a cigarette 
(Panel B).  Individuals smoke the cigarette through the mouthpiece.  The device measures and 
records a number of smoking topography parameters, namely: (1) number of puffs per cigarette, 
(2) puff duration, (3) inter-puff interval, (4) puff volume, and (5) maximum puff velocity.  All 
data are transferred from the console to a desktop PC via a USB cord.   
 
 




Smoking Topography Parameters 
Description: A representation of two puffs and corresponding puff topography parameters as 


















Modified Cigarette Evaluation Questionnaire (mCEQ) 
Description: A 12-item questionnaire assessing how smoking a cigarette made the participant 
feel.  Participants answer each question with a Likert scale ranging from one to seven.  An answer 
of zero indicates “not at all”, and seven indicates “extremely”.  Certain items are averaged to 
create subscale scores. The mCEQ is made up of five subscales (i.e., Satisfaction, Psychological 






Not at all Extremely 
Satisfaction Was smoking satisfying? 1 2 3 4 5 6 7 
Satisfaction Did the cigarette taste 
good? 





Did you enjoy the 
sensations in your throat 
and chest? 
1 2 3 4 5 6 7 
Psychological 
Reward 
Did smoking calm you 
down? 
1 2 3 4 5 6 7 
Psychological 
Reward 
Did smoking make you 
feel more awake? 
1 2 3 4 5 6 7 
Psychological 
Reward 
Did smoking make you 
feel less irritable? 
1 2 3 4 5 6 7 
Psychological 
Reward 
Did smoking help you 
concentrate? 
1 2 3 4 5 6 7 
Psychological 
Reward 
Did smoking reduce 
your hunger for food? 
1 2 3 4 5 6 7 
Aversion Did smoking make you 
dizzy? 
1 2 3 4 5 6 7 
Aversion Did smoking make you 
nauseous? 




immediately reduce your 
craving for cigarettes? 
1 2 3 4 5 6 7 








Minnesota Nicotine Withdrawal Scale (MNWS) 
Description: The MNWS measures nicotine withdrawal symptoms.   Participants reported on the 
presence of a given symptom with an answer of ‘None’, ‘Slight’, ‘Mild’, ‘Moderate’, and 
‘Severe’.  Responses were then assigned a score of 0 to 4, with 0 representing None and 4 
reflecting Severe.  Mean withdrawal is derived as the average of seven of the eight symptoms 
(range, 0-4), with the item “Desire or Craving to Smoke” analyzed separately (Hughes & 













1) Angry, irritable, frustrated      
2) Anxious, nervous      
3) Depressed mood, sad      
4) Desire or craving to smoke      
5) Difficulty concentrating      
6) Increased appetite, hungry, weight 
gain 
     
7) Insomnia, sleep problems, awakening 
at night 
     









Questionnaire of Smoking Urges (QSU) 
Description: The QSU is comprised of 10 statements regarding current cravings to smoke. 
Participants assigned each statement a number from one to seven. An answer of zero indicates 
“strongly disagree”, and seven indicates “strongly agree”.  The QSU is scored such that two 
factors are derived, with Factor 1 often described as a measure of positive reinforcing effects of 
smoking and Factor 2 a measure of the negative reinforcing effects of smoking..  Factor scores 
are calculated by averaging scores from the individual item scores that make up each factor 
(Factor 1 = six items, Factor 2 = four items).  Factor scores range from 1 to 7. Higher scores 
indicate greater craving/urges to smoke. 
 
 
Factor Question Strongly  
DISAGREE 
    Strongly 
AGREE 
1 I have a desire for a 
cigarette right now 
1 2 3 4 5 6 7 
1 Nothing would be better 
than smoking a cigarette 
right now. 
1 2 3 4 5 6 7 
1 If it were possible, I 
probably would smoke 
right now. 
1 2 3 4 5 6 7 
2 I could control things 
better right now if I 
could smoke. 
1 2 3 4 5 6 7 
2 All I want right now is a 
cigarette. 
1 2 3 4 5 6 7 
1 I have an urge for a 
cigarette. 
1 2 3 4 5 6 7 
1 A cigarette would taste 
good right now 
1 2 3 4 5 6 7 
2 I would do almost 
anything for a cigarette 
right now. 
1 2 3 4 5 6 7 
2 Smoking would make 
me less depressed. 
1 2 3 4 5 6 7 
1 I am going to smoke as 
soon as possible. 
1 2 3 4 5 6 7 
